Please try another search
Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient’s blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Name | Age | Since | Title |
---|---|---|---|
Mark D. Pegram | - | - | Member of Breast Cancer Advisory Board |
Raymond R. Tubbs | - | - | Member of Breast Cancer Advisory Board |
Michael F. Press | - | - | Member of Breast Cancer Advisory Board |
Kenneth J. Bloom | 66 | - | Member of Breast Cancer Advisory Board |
Tina S. Nova | 70 | 2019 | Executive Chairman of the Board of Directors |
Thomas Williams | - | - | Member of Breast Cancer Advisory Board |
David T. Rubin | - | - | Member of Science Advisory Board |
Anca Dinu Askanase | - | 2019 | Member of Scientific Advisory Board |
Ebetuel Pallares | 51 | 2012 | Independent Director |
Bruce C. Robertson | 61 | 2019 | Independent Director |
Harris Perlman | - | 2022 | Member of Rheumatoid Arthritis Scientific Advisory Board |
Kevin Deane | - | 2022 | Member of Rheumatoid Arthritis Scientific Advisory Board |
John Aballi | 39 | 2022 | CEO, President & Director |
Stanley B. Cohen | - | 2022 | Member of Rheumatoid Arthritis Scientific Advisory Board |
Andrew L. Concoff | - | 2019 | Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board |
Vasileios Kyttaris | - | 2019 | Member of Scientific Advisory Board |
Joel M. Kremer | - | - | Member of Scientific Advisory Board |
Paul J. DeMarco | - | 2022 | Member of Rheumatoid Arthritis Scientific Advisory Board |
Frank Stokes | 53 | 2021 | Independent Director |
Arthur Weinstein | 80 | 2013 | Chairman of Scientific Advisory Board |
Ana Hooker | 57 | 2021 | Independent Director |
Eric M. Ruderman | - | 2022 | Member of Rheumatoid Arthritis Scientific Advisory Board |
Marina Sirota | - | 2022 | Member of Rheumatoid Arthritis Scientific Advisory Board |
Wendy S. Johnson | 72 | 2020 | Independent Director |
Maureen A. McMahon | - | 2019 | Member of Scientific Advisory Board |
Paul Kim | 57 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review